Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/31232
Title: A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Authors: 
Keywords: 
Mesh: 
Issue Date: Oct-2017
Citation: Breast Cancer Res. Treat..2017 Oct;(165)3:601-609
Abstract: To evaluate whether adding humanized monoclonal insulin growth factor-1 receptor (IGF-1R) antibody (dalotuzumab) to mammalian target of rapamycin (mTOR) inhibitor (ridaforolimus) plus aromatase inhibitor (exemestane) improves outcomes in patients with estrogen receptor (ER)-positive advanced/metastatic breast cancer.
PMID: 28681171
URI: https://hdl.handle.net/20.500.12530/31232
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5709225.pdf558 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.